Marina Naldi, Antonio Bruno, Nazzareno Galiè, Maria-Letizia Bacchi-Reggiani, Chiara Barozzi, Manuela Bartolini, Mario Marengo, Gianfranco Cicoria, Luciana Tomasi, Gregg W. Stone, Diego Della Riva, Stefano Fanti, Tullio Palmerini, Palmerini, Tullio, Barozzi, Chiara, Tomasi, Luciana, Riva, Diego Della, Marengo, Mario, Cicoria, Gianfranco, Bruno, Antonio G., Bacchi-Reggiani, Maria-Letizia, Naldi, Marina, Bartolini, Manuela, Fanti, Stefano, Galiè, Nazzareno, and Stone, Gregg W.
Aims: We sought to investigate the thrombogenicity of different DES and BMS in an in vitro system of stent perfusion. Material and methods: The experimental model consisted of a peristaltic pump connected to 4 parallel silicone tubes in which different stents were deployed. Blood was drawn from healthy volunteers and the amount of stent surfaced-induced thrombus deposition was determined using 125I-fibrinogen. Results: Compared to Resolute, Biomatrix and Vision, Xience was associated with the lowest amount of stent surface-induced thrombus formation, with a significant difference compared to Vision (125I-fibrinogen median value deposition [IQ range]: 50 ng [25-98] versus 560 ng [320-1520], respectively, p < 0.05), but not to other DES. In the second set of experiments Fluoropolymer-coated BMS not eluting drug was associated with a significant 3-fold reduction in 125I-fibrinogen deposition (245 ng [80-300]) compared to Vision (625 ng [320-760], p < 0.05), but a 7-fold increase compared to Xience (35 ng [20-60], p < 0.05). Finally Xience was associated with a significantly greater absorption of albumin compared to BMS. Conclusions: In an in vitro system of stent perfusion, Xience was associated with the lowest amount of stent surface-induced thrombus formation compared with Resolute, Biomatrix and Vision, with a noted synergistic effect between the fluoropolymer and the drug.